Related Experiment Video

Updated: Jun 27, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

MRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic

F Mahjoubi1, S Akbari, M Montazeri

  • 1Clinical Genetics Department, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. Frouz@nigeb.ac.ir

Genetics and Molecular Research : GMR
|December 11, 2008
PubMed

Insights

High expression of multidrug resistance protein 1 (MRP1) correlates with multidrug resistance (MDR) in acute leukemia patients. However, MRP1 gene polymorphisms do not predict MDR or affect chemotherapy response in these patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Cancer cells can develop resistance to multiple anticancer drugs, a phenomenon known as multidrug resistance (MDR).
  • Drug-efflux transporters, such as multidrug resistance protein 1 (MRP1), are implicated in MDR.
  • Understanding the role of MRP1 in leukemia MDR is crucial for improving treatment outcomes.

Purpose of the Study:

  • To investigate the association between MRP1 expression levels and MDR in acute leukemia patients.
  • To determine if MRP1 gene polymorphisms predict MDR in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients.
  • To assess the impact of MRP1 genotypes on chemotherapy response.

Main Methods:

  • Quantitative real-time PCR was used to measure MRP1 mRNA levels in 111 acute leukemia patients (52 AML, 59 ALL).
  • Specific MRP1 polymorphisms (T2684C, C2007T, C2012T, C2665T) were genotyped in the same patient cohort.
  • Patients were classified as either drug-resistant or drug-responsive based on their response to chemotherapy.

Main Results:

  • Elevated MRP1 expression was significantly associated with the MDR phenotype in both AML and ALL patients.
  • No significant association was found between specific MRP1 genotypes and MRP1 gene expression levels.
  • No significant differences in chemotherapy sensitivity were observed among the studied MRP1 genotypes.

Conclusions:

  • High MRP1 expression is linked to multidrug resistance in acute leukemia.
  • MRP1 gene polymorphisms do not appear to be predictive markers for MDR or chemosensitivity in acute leukemia.
  • Further research may be needed to identify other factors contributing to MDR in leukemia.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...